Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-5635 alone or in combination in previously treated chronic hepatitis B
CTR20241805Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jun 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5635 in Chronic Hepatitis B (CHB), sponsored by Fujian Shengdi Pharmaceuticals. Started Jun 2024; status: active.
02
Drugs
HRS-5635
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20241805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241805.